TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maintenance of response at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity measured by six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity measured by shuttle walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in executive cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Short-Term Graft Superiority
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-Term Graft Superiority
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage reduction of seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time-averaged serum glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Titers of Anti-HPV-16 and Anti-HPV-18 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Thromboelastography parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transport of iodide ions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of Ability to Swallow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise endurance time (EET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal temperature (in degrees Celsius) at isotime during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femorotibial mismatch angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of YM150
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to diagnosis conclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative pain evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Uterine Endometrial Contractions Per Minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Work incapacitation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Peak pressure associated with injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The duration of peak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Joint Engagement on the Caregiver-child interaction (CCX)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Physiological sleep architectural quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Eligible for Sub-study Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tumoral uptake of [18F]GE-226 (semi-quantitative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumoral uptake of [18F]GE-226 (fully quantitative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUC0-t of lamotrigine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of exCR sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of volume change of whole brain and other structural MRI measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Episodic memory as measured by Cognitive Tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in patency of target veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Agreement between transcutaneous and arterial carbon dioxide partial pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance status at diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical and/or pathological stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of other primary tumors
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Medium Pressure Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of New Onset of Diabetes After Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cessation of PPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: device-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Composed-Anxious Subscale of POMS-Bi
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of antibiotic resistant bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical/radiological response rate for CLL subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean of Wall Volume of Internal Carotid Arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 1-minute Schirmer's test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parents' Postnatal Sense of Security
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy on asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy on lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy on severe exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fractional Excretion of Sodium (FEna)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Healing of scarred vocal folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived attitudes towards lifestyle interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Onset of Effect in the Spontaneous NRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Effect in the Spontaneous NRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Effect in the Spontaneous NRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma pentraxin-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to regulate infant body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events as assessed by staff observation
Endpoint domain: Adverse events/effects
Primary endpoint: Time until any treatment-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: toxicities of Melphalan
Endpoint domain: Adverse events/effects
Primary endpoint: Single Dose PK: Area Under the Plasma Concentration Curve From 0-28 Days (AUC[0-28 Days]) of Pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of donor twin at 30 days after birth
Endpoint domain: Mortality/survival
Primary endpoint: Survival of recipient twin at 30 days after birth
Endpoint domain: Mortality/survival
Primary endpoint: Acceptance with COVID-19 Virtual Post Intensive Care Syndrome Visits - AIM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance with COVID-19 Virtual Post Intensive Care Syndrome Visits - IAM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance with COVID-19 Virtual Post Intensive Care Syndrome Visits - FIM
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Postoperative Nausea and/or Vomiting (PONV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intratumoral androgen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Level of nutrition knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mitral valve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Fasting Blood Sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Postprandial sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: therapeutic effect of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of antithymocyte globulin and cyclosporine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of antithymocyte globulin and cyclosporine
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Exhibiting 3 Fold Rise in Rotavirus Specific Serum IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Exhibiting 3 Fold Rise in G1 Serum Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Exhibiting 3 Fold Rise in G2 Serum Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in MG-ADL score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cocaine Use by Quantitative Urine Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of patients with LDL-C level ≥ 4.14 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Blood Pressure Measurements at Least Once Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mean Vessel Wall Area (VMA) of the Carotid Bulb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of crenolanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine ghrelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of Life after Brain Injury (QOLIBRI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Charlson Comorbidity List
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Traumatic Brain Injury (TBI) Symptom and Functional Status Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mayo-Portland Adaptability Inventory - IV (MPAI-4)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage change from PRE-Prolaris® test treatment option
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate at 48 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of purulent collections superior to 2 cms concerning the fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of fever and local inflammatory symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Successful completion of radical prostatectomy without post-operative DLT of grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: safety and effectiveness of bivalirudin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent changes in mean sitting systolic blood pressure (MSSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent changes in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cigarette smoking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parent Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ki67 proliferative surrogate biomarker expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial Length of eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full-scale intelligence quotient (FSIQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Optimal Dose of Neuromuscular Blocking Agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Drug Related Adverse Events (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive Complaints
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Professional Recovery
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximum plasma concentration (Cmax) of diclofenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration curve (AUC0-t) of diclofenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration curve (AUC0-t) of tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hepatitis C Virus RNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Devitalized tissue reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly % Healthy Food Expenditure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum lesion standardized uptake value (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory Evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Assessment of Cancer Therapy Scale (FACT)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in submaximal 6-min walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of pain in the body
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: HDL-cholesterol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MINI-Tinnitus Questionnaire (Mini-TQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-day Point Prevalence All Tobacco Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Colorectal Cancer Screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Log-transformed change in Antibody Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in AF-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median Platelet Count >= 50,000/uL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients showing complete voluntary micturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in urgency urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fugl-Meyer Upper Limb Coordination Scale (FMUE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Anti HEV-IgM and IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Force over time during a manual muscle test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Force during a maximal voluntary isometric contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Seroconverted Subjects Against HPV-16 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) for HPV-16 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects Against HPV-18 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) for HPV-18 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Asthma Control Questionnaire (ACQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with plasma viral load below 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alzheimer disease incidence
Endpoint domain: Mortality/survival
Primary endpoint: Dementia prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Intracranial disease control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Asthma Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Allergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerability of skin-RF interactions
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of skin-RF interactions
Endpoint domain: Adverse events/effects
Primary endpoint: Gait Speed Normal Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Speed Dual-task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive Function Composite z Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Presence and Severity of Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of metabolic acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Step-count bout ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serious post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in renal stone position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: skin burn lesion
Endpoint domain: Adverse events/effects
Primary endpoint: exhalative nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: metacholine testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Initial presentation of cardiovascular diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of somatic symptoms disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoglobulin G (IgG) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Counts per minute at time point T=0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counts per minute at time point T=1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic pain experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical re-bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematic Levels of Hepatic Enzymes AST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematic Levels of Hepatic Enzymes ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematic Levels of Hepatic Enzymes GGT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Time Bispectral Index (BIS) Remains +/- 10 of Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sphericity deviation score of the femoral head
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in neutrophil apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in neutrophil receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal apelinemia (Plasma Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Assessment (IGA) Treatment Success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of surgeon efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of surgeon proficiency/performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Spastic Paraplegia Rating Scale (SPRS) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes